Ten years of achievements in biological and medical sciences Editorial First Online: 18 February 2017 Received: 26 December 2016
Dr. Mingyao Liu received his Ph.D. Degree in Cell Biology from the University of Maryland, College Park in 1992. From 1993 to 1998, he did his postdoctoral trainings in Johns Hopkins University School of Medicine and California Institute of Technology (Caltech) with Prof. King-Wai Yau and Melvin I Simon. In 1999, he was recruited to the Institute of Biosciences and Technology, Texas A&M University as an assistant professor, then promoted to associate professor in 2003 and full professor with tenure in 2007. In 2007, Dr. Liu was recruited as the director of the Institute of Biomedical Sciences, then appointed as the dean of School of Life Sciences and the director of Shanghai Key Laboratory of Regulatory Biology, East China Normal University, China in 2012. Together with his colleagues, Dr. Liu established a laboratory for cell signaling and innovative drug discovery. In 2008, he was selected as the Distinguished Endowed Professor by “The Recruitment Program of Global Experts”. In 2014, he was awarded Shanghai Magnolia Prize and First Prize of National Scientific and Technological Progress Award.
Dr. Tieliu Shi received his Master degree in computer science in 1999 and Ph.D. degree in molecular biology in 2000 from the University of Louisville. After graduate school, he pursued bioinformatics research and joined the Bioinformatics Center, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences between 2002 and 2008. He moved to East China Normal University by the end of 2008 and served as full professor. He has various research interests, including (1) Disease gene, disease mechanism and biomarker discoveries based on multi-level data integration of omics and clinical information; (2) Methodology developments and applications in the high through-put data (NGS data, proteomic data, etc.); (3) Gene regulatory network prediction and protein-protein interaction network prediction; (4) Drug target, drug efficacy and adverse prediction, including Traditional Chinese Medicine.
Dr. Jiemin Wong received his bachelor degree in Biology in 1984 from Wuhan University, M.S. degree in Cell Biology in 1987 from Shanghai Institute of Cell Biology and Ph.D. degree in Molecular Genetics and Microbiology in 1994 from University of Vermont. He had his postdoc training in NIH during 1994–1997. He joined the Dept of Molecular and Cellular Biology, Baylor College of Medicine as an Assistant Professor in 1997 and promoted to tenured Associate Professor in 2003. Dr. Wong joined the School of Life Sciences and the Institute of Biomedical Sciences in East China Normal University in 2007 and since then has served as Professor and Associate Director for the Institute of Biomedical Sciences. Dr. Wong’s laboratory has long been interested in epigenetic regulation and transcriptional regulation by nuclear hormone receptors (NRs). His group has made contribution to the identification and characterization of the corepressor complexes of nuclear hormone receptors, histone demethylases and identification and characterization of histone code effectors. He has published more than 100 peer-reviewed papers. His current research focuses on epigenetic regulation including DNA methylation and histone modifications.
Dr. Dali Li completed his B.S. degree in 2001 and obtained his Ph.D. degree in Genetics from Hunan Normal University in 2007. As a visiting scholar, he joined Mingyao Liu’s lab in Texas A&M University Health Science Center in 2004–2007. He became a lecture in School of Life Sciences, East China Normal University in 2007 and was promoted to Professor in 2014. He has set up and directs the transgenic core facility in ECNU. He is interested in applying and developing of novel genome modification technologies for disease model generation and
in vivo gene therapy.
Dr. Yuping Lai received her Ph.D. degree from East China Normal University in 2006. After her graduate school, which included an NIH/NIAID predoctoral fellowship, Yuping moved to Dr. Gallo’s lab in University of California-San Diego and began to investigate the relationships between microbes and their hosts, especially how
Staphylococcus epidermidis influences skin immune responses. In 2010 Yuping moved back to China and started her own laboratory in East China Normal University. Now her research interests are focused on understanding innate immune responses involved in wound infection, inflammation and wound healing, especially including: (1) investigating the functions of REG3A in wound healing, wound inflammation and the pathogenesis of psoriasis; (2) exploring the mechanisms by which IL-1 family cytokines induce REG3A in keratinocytes; (3) understanding how hyperglycemia facilitates Staphylococcus aureus skin infection in diabetes.
Dr. Yuan Wang obtained her Ph.D. degree from Boston University in Molecular and Cell Biology and Biochemistry in 2002. She completed her post-doc training at Harvard Medical School and NIEHS afterwards. Dr. Wang joined East China Normal University as a professor in 2009. The main research focus of Dr. Wang’s lab is to dissect the genetic programs that govern germ cell and blood differentiation using both
in vitro differentiation system of PSCs and gene modified mouse models. She is also interested in molecular mechanism that regulates self-renewal of PSCs.
Dr. Min Qian completed her B.S. degree at East China Normal University in 1983. After that, she earned her Master degree at East China Normal University in 1986. Then, she began her assistant professor position at Suzhou University of Science and Technology from 1986 to 1988. She obtained her PhD degree at East China Normal University in 1991 and then served as an assistant professor at East China Normal University, and has been a full professor of immunology since 2002. She is interested in exploring specific human antibody to different drug targets by using phage display technology. Meanwhile, she is also involved in understanding the regulation of innate immune responses in inflammation, cancer and infectious diseases.
Dr. Bing Du completed his B.S. degree in biochemistry from Anhui University in 2001. After that, he earned his Ph.D. degree in biochemistry and molecular biology at East China Normal University in 2006. Since then, he began his assistant professor position at East China Normal University, and is now an associate professor of immunology from 2010. In this period, he joined Dr. Mingyao Liu’s laboratory as a visiting scholar for more than 1 year at Texas A&M Institute of Biosciences and Technology in Houston. His research interests are in understanding the molecular mechanisms of macrophage mediated innate immune responses in inflammation, cancer and infectious diseases.
Dr. Xiufeng Pang received her Ph.D. degree in 2009 from the joint program between East China Normal University (ECNU), Shanghai, China, and Texas A&M University Health Science Center, Texas, US. Upon her completion of Ph.D. training, she joined School of Life Sciences, ECNU as a research associate and studies in the fields of anticancer drug discovery and molecular pharmacology. In 2012, Dr. Pang became an associate professor and the main leader of anticancer drug screening section, Shanghai key laboratory of regulatory biology. Dr. Pang published more than 30 articles on high-impact biological and pharmacological journals, such as
Nature Communications, Cancer Research, Molecular Cancer Therapeutics, Carcinogenesis, and Journal of Medicinal Chemistry, etc. She got several grants from National Natural Science Foundation, Shanghai Municipal Education Commission and Science and Technology Commission of Shanghai Municipality. Dr. Pang is the recipient of Chenguang Research Award from Shanghai Municipal Education Commission, State Scholarship from China Scholarship Council and Biovision.Nxt. Award from International Bioscience Forum. Her major scientific focus includes novel anticancer drug development, clinical anticancer drug resistance and combined therapy.
Dr. Zhengfang Yi is a professor and an investigator in the Biomedical research Institute at East China Normal University, Shanghai, China. He received his master’s degree from Hunan Normal University (Hunan, China) in 2004. He obtained his Ph.D. from East China Normal University and the Texas A&M University (USA). He was promoted to Associate Professor in 2010 and to Professor in 2015. He is interested in the development of new drugs for tumor (prostate cancer, breast cancer, leukemia, colon cancer, liver cancer) as well as new medical devices.
Dr. Xin Wang received his Ph.D. degree in pharmacology from the Chinese University of Hong Kong in 2007, and completed his postdoctoral training in the University of Texas Medical Branch in 2011. He has been working in the East China Normal University as associate professor since 2011. Dr. Wang has the honor to win the Youth Pharmacologist Award of Chinese Pharmacological Society in 2016. His research fields include pharmacokinetics and drug metabolism, especially drug-drug interactions, and novel models for ADME, such as 3D organoids of transporter protein, CYP knockout rat and humanized rat model. Currently, Dr. Wang is hosting or participating in many projects supported by the Science and Technology Commission of Shanghai Municipality and the National Natural Science Foundation of China. Dr. Wang has published more than 40 SCI papers in international peer-reviewed journals, such as
Nature Communications, Biochemical-Pharmacology, and Pharmacological Research, etc. Moreover, he also edited one pharmacological book, and contributed four book chapters. Meanwhile, he is dedicated to social activities and serves as the editorial board member and ad-hoc reviewer of 27 SCI journals, such as Biochemical Pharmacology, Journal of Pharmaceutical and Biomedical Analysis, and Current Drug Metabolism, etc.